Relypsa Inc (RLYP) : Sphera Funds Management Ltd. added new position in Relypsa Inc during the most recent quarter end. The investment management firm now holds 130,000 shares of Relypsa Inc which is valued at $4,153,500 , the company said in a statement filed on Aug 10, 2016 with the SEC.Relypsa Inc makes up approximately 0.96% of Sphera Funds Management Ltd.’s portfolio.
Other Hedge Funds, Including , Tower Research Capital (trc) added RLYP to its portfolio by purchasing 4,261 company shares during the most recent quarter which is valued at $136,139. Relypsa Inc makes up approx 0.01% of Tower Research Capital (trc)’s portfolio. Janney Montgomery Scott added RLYP to its portfolio by purchasing 9,244 company shares during the most recent quarter which is valued at $295,161.Diam Ltd. reduced its stake in RLYP by selling 6,630 shares or 2.56% in the most recent quarter. The Hedge Fund company now holds 252,844 shares of RLYP which is valued at $8,068,252. Relypsa Inc makes up approx 0.12% of Diam Ltd.’s portfolio.Creative Planning reduced its stake in RLYP by selling 190 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 11,510 shares of RLYP which is valued at $230,085.
Relypsa Inc opened for trading at $31.92 and hit $31.96 on the upside on Friday, eventually ending the session at $31.96, with a gain of 0.13% or 0.04 points. The heightened volatility saw the trading volume jump to 12,37,520 shares. Company has a market cap of $1,434 M.
On the company’s financial health, Relypsa Inc reported $-1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on May 4, 2016. Analyst had a consensus of $-1.44. The company had revenue of $12.40 million for the quarter, compared to analysts expectations of $7.10 million. During the same quarter in the previous year, the company posted $-0.78 EPS.
Many Wall Street Analysts have commented on Relypsa Inc. Relypsa Inc was Downgraded by Stifel to ” Hold” on Aug 22, 2016. Relypsa Inc was Downgraded by Cantor Fitzgerald to ” Hold” on Jul 26, 2016. Relypsa Inc was Downgraded by Guggenheim to ” Neutral” on Jul 26, 2016.
Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.